about
Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsEvidence of impaired cisapride metabolism in neonatesEffects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trialEffects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmiaReview article: the safety profile of tegaserod.Review article: cardiac adverse effects of gastrointestinal prokinetics.Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes.Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycinMechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue.Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.Effect of oral erythromycin on gastric and small bowel transit time of capsule endoscopyAldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia.Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.Risk factors for drug-induced long-QT syndrome.Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and TherapeuticsCisapride-induced torsades de pointes.Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres.Effects of cisapride on QTc interval in neonates.Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects.Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.The effect of metoclopramide on QT dynamicity: double-blind, placebo-controlled, cross-over study in healthy male volunteers.
P2860
Q28071256-FC2E33DA-5C58-48E4-8B16-FA8F94DAC873Q28362557-2244CBE1-82FE-40C8-B702-10D0FEFB29CBQ28364173-102FD12D-342C-48CB-9B71-F49962653850Q28377348-4349CC99-146D-484C-9150-20B729284E8CQ33432438-1159A65B-515B-44C8-AC2A-274AAD856D34Q33792373-E5FE4ED1-B4AF-4D6D-8DAF-712D59D261FBQ33844131-4A4E2AF8-2B84-41F0-85A8-75D15823C17EQ34049823-A6F755FB-E136-4F54-AEA5-0F9DA074F95EQ34633457-47F3D90F-B3CC-4A2E-825C-8A8CF47695C7Q34752070-94DF9387-9A1B-49BD-8F27-8BEBA4C9E092Q35041505-AAC39236-080E-4079-9534-A3234362658EQ35435788-CECF2AC8-81F9-4944-A975-50C251E9C2AAQ36333444-2FBF30F4-6912-44E0-A624-C774A65C3B0FQ39414529-FE5BEA30-390C-4E57-8E9E-CF1A2F23B820Q39784655-1067DB6C-A529-4552-957E-D40F512607B3Q42340044-13A5D223-2CEB-4EB3-BC21-1974FB7DC057Q42361532-D5AA8703-DDBB-400C-8C2E-0E88B913E785Q42538260-FDC65BCB-14BB-4C40-9559-E59C8009C171Q42705312-7E90C337-187D-4435-91A8-83F6226B5C28Q43098123-ADB58A2F-E465-4692-927D-436181385ABAQ43648681-0C169357-5F7D-4F66-B376-B7C24115E9C1Q43782284-099F6431-9E78-4C04-B780-46CBA0CC8B65Q44162437-9049C31C-3614-433C-BD4F-C36F5AC4AAF7Q44505189-F0A9C408-78C9-4CCB-97F6-9CE6D3517DD3
P2860
description
1995 nî lūn-bûn
@nan
1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Long QT syndrome during high-dose cisapride.
@ast
Long QT syndrome during high-dose cisapride.
@en
type
label
Long QT syndrome during high-dose cisapride.
@ast
Long QT syndrome during high-dose cisapride.
@en
prefLabel
Long QT syndrome during high-dose cisapride.
@ast
Long QT syndrome during high-dose cisapride.
@en
P2093
P1476
Long QT syndrome during high-dose cisapride.
@en
P2093
P304
P356
10.1001/ARCHINTE.155.7.765
P407
P577
1995-04-01T00:00:00Z